Dashboard
Financial statements
ABBV

Company financials

AbbVie

Health Care Biotechnology North Chicago, Illinois Last filing Feb 20, 2026 · FY2025
Revenue FY2025
$61.2B
3y CAGR +1.8% P29
Net income FY2025
$4.2B
Net margin +6.9% P25
Total assets FY2025
$134.0B
ROA +3.2% P25
Operating cash flow FY2025
$19.0B
FCF margin +29.1% P96
15 yrs · FY2011–FY2025 8 filed · 1 derived · 0 blank

Each cell as a share of that year’s total assets.

Balance Sheet

Assets, liabilities, and equity

26 accounts · 3 years
Total assets $134.0B
Total liabilities ~$137.2B
Shareholders equity $-3.3B
Account 2025 2024 2023 Trend
Assets
Cash and Cash Equivalents 3.9% 4.1% 9.5%
Short Term Investments 0.0% 0.0% 0.0%
Accounts Receivable 9.4% 8.1% 8.3%
Inventory 3.7% 3.1% 3.0%
Prepaid Expenses 4.7% 3.6% 3.7%
Total Current Assets 21.7% 18.9% 24.5%
Property,Plant and Equipment 4.2% 3.8% 3.7%
Goodwill 26.6% 25.9% 24.0%
Intangible Assets 39.3% 44.4% 41.3%
Long Term Investments 0.2% 0.2% 0.2%
Other Noncurrent Assets 8.0% 6.8% 6.3%
Total Assets 100.0% 100.0% 100.0%
Liabilities
Accounts Payable 25.9% 23.6% 22.8%
Current Portion of Long Term Debt 6.4% 5.0% 5.3%
Total Current Liabilities 32.3% 28.7% 28.1%
Long Term Debt 44.0% 44.6% 38.7%
Deferred Tax Liabilities 1.8% 1.9% 1.4%
Other Noncurrent Liabilities 24.3% 22.3% 24.0%
Equity
Common Stock 0.0% 0.0% 0.0%
Additional Paid In Capital 16.8% 15.8% 15.0%
Retained Earnings -11.6% -5.8% -0.7%
Treasury Stock 6.8% 6.1% 4.8%
Accumulated Other Comprehensive Income -0.9% -1.4% -1.7%
Total Stockholders Equity -2.4% 2.5% 7.7%
Noncontrolling Interest 0.0% 0.0% 0.0%
Total Liabilitiesand Equity 100.0% 100.0% 100.0%

Key Ratios

Margins, returns, liquidity, leverage, efficiency

Computed at import · 3 years
Ratio 2025 2024 2023
Profitability
Gross margin +70.2% +70.0% +62.4%
Operating margin +24.6% +16.2% +23.5%
Net margin +6.9% +7.6% +9.0%
FCF margin +29.1% +31.7% +40.6%
Growth
Revenue CAGR (3y) +1.8% +0.1% +5.8%
Returns
ROE -129.2% +128.7% +46.9%
ROA +3.2% +3.2% +3.6%
ROIC +16.4% +14.1% +17.5%
Liquidity
Current ratio 0.67x 0.66x 0.87x
Quick ratio 0.41x 0.42x 0.63x
Leverage
D/E -41.97x 39.65x 12.00x
Interest coverage 5.74x 4.23x 7.58x
Efficiency
Asset turnover 0.46x 0.42x 0.40x
Cash conversion cycle -522d -529d -400d

Valuation

Price against fundamentals

ABBV $218 · 2025-09-12 · 414d old · FY2025
Market cap $387.1B
P/E 91.60x
P/S 6.33x
P/B —
EV $449.4B
EV/EBITDA —
FCF yield +4.6%
Dividend yield +3.0%

Notes

Your annotations

Not watched
Saving notes adds ABBV to your watchlist.